scholarly journals The Effect of Citicoline on Electroretinography Abnormalities in Patients with Non-proliferative Diabetic Retinopathy

2019 ◽  
Vol 2 (1) ◽  
Author(s):  
Anna Nur Utami ◽  
Elvioza Elvioza ◽  
M Sidik
Keyword(s):  
Diabetic Retinopathy ◽  
Proliferative Diabetic Retinopathy ◽  
Primary Outcome ◽  
Positive Trend ◽  
Exclusion Criteria ◽  
Double Blind ◽  
P Values ◽  
Oral Supplementation ◽  
End Of Treatment ◽  
Before And After

Introduction : to determine the effect of citicoline 1000 mg oral supplementation given for 4 weeks on electroretinography abnormalities in patients with NPDR (non-proliferative diabetic retinopathy). Methods : prospective, double blind, randomized clinical trial. Thirty-eight patients who matched the inclusion and exclusion criteria were randomized into two groups: the placebo (P-NPDR) and citicoline (C-NPDR).  In the end, there were 18 eyes in citicoline group and 16 eyes in placebo group. The primary outcome was P50 and N95 amplitude in PERG within group and intergroup which were taken at the baseline and 4 weeks after treatment. Results : at the end of treatment, the N95 amplitude in C-NPDR showed improvement, 4.85 (1.9-10.3) µV, before treatment to 5.7 (1.9-17.1) µV, after treatment with P = 0.04. Median P50 amplitude improved in both groups, with C-NPDR: 3.1 µV to 3.8 µV (p = 0.89), and P-NPDR: 3.5 µV, to 4.5 µV (p = 0.10). Delta ∆N95 amplitude is higher in C-NPDR, while delta ∆P50 amplitude is higher in P-NPDR, with P values 0.35 and 0.45. Conclusion : Oral citicoline may induce a significant improvement in mean N95 amplitude before and after the treatment. P-NPDR showed positive trend in P50 amplitude while in C-NPDR showed positive trend in N95 amplitude, but these values were not statistically significant (P = 0.45; P= 0.35).

OCT-Angiography as a reliable prognostic tool in laser-treated proliferative diabetic retinopathy: The RENOCTA Study

2020 ◽  
pp. 112067212096345
Author(s):  
Marco Lupidi ◽  
Ramkailash Gujar ◽  
Alessio Cerquaglia ◽  
Jay Chhablani ◽  
Daniela Fruttini ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Proliferative Diabetic Retinopathy ◽  
Additional Treatment ◽  
Post Treatment ◽  
Vascular Perfusion ◽  
Significant Difference ◽  
Before And After ◽  
The Mean ◽  
Pre Treatment ◽  
Induced Changes

Purpose: To quantitatively assess retinal neovascularizations (RNVs) in proliferative diabetic retinopathy (PDR) before and after photocoagulative laser treatment (PLT) using Optical Coherence Tomography Angiography (OCT-A). Methods: Consecutive patients with PDR were examined with fluorescein angiography (FA) and OCT-A before and after PLT. Baseline and after-treatment FA images were quantitatively analyzed to assess both the RNVs area and leakage area. On OCT-A RNVs area, vascular perfusion density (VPD), vessel length density (VLD) and fractal dimension were computed. VPD of the full-retina OCT-A underneath the RNV was determined to evaluate potential laser-induced changes in vascular perfusion. Results: Fifteen eyes of 13 patients with PDR were enrolled. The mean area of the RNVs was 0.47 ± 0.50 mm2 in the baseline OCT-A and 0.32 ± 0.40 mm2 in the post-treatment assessment ( p = 0.0002). The mean RNV VPD of RNV was 2% ± 4% in pre-treatment and 1% ± 1% for the post-treatment ( p = 0.0001). The mean VLD of RNV was 7.26 ± 1.53 at baseline and 6.64 ± 1.65 in the post treatment ( p = 0.0002). A significant difference in terms of mean RNVs area and VPD reduction between eyes that needed additional treatment and those that did not (~40% vs ~20%; p < 0.05), was observed. Mean VPD of full-retinal thickness OCT-angiogram was 55% ± 10% for the pre-treatment and 53% ± 8% for the post treatment scan ( p = 0.02). Conclusion: The quantitative OCT-A assessment of laser-induced changes of RNVs can be a useful non-invasive approach for determining treatment efficacy. A reduction of RNVs area or VPD ⩾ 40% might reveal those eyes that won’t require additional treatment. Retinal perfusion impairment seemed to progress independently from the treatment.

scholarly journals N-Acetylcystein has Potential Effect to Reduce Haematological Abnormalities in HIV/AIDS Patients Undergoing ARV Treatment

2020 ◽  
Vol 10 (4-s) ◽  
pp. 197-200
Author(s):  
Filia Yuniza ◽  
Eddy Mart Salim ◽  
Nova Kurniati ◽  
Harun Hudari ◽  
Erial Bahar ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Placebo Group ◽  
Potential Effect ◽  
Aids Patients ◽  
Exclusion Criteria ◽  
Double Blind ◽  
Before And After ◽  
The Mean ◽  
Hematological Abnormalities ◽  
Hiv Aids

Aims: to determine the effect of NAC administration on hematological abnormalities in HIV/AIDS patients who are undergoing ARV treatment. Method: This was a pilot study using a double blind randomized clinical trial. A total of 32 subjects who met the inclusion and exclusion criteria were divided into 2 groups, namely placebo and NAC. Subjects in the NAC group were given NAC at a dose of 3x200 mg/day, while the placebo group was given lactose at a dose of 3x200 mg/day. Each group was given treatment for 12 weeks. Before and after treatment, subjects were examined for hematologic parameters. Results:  Most of subjects had normal hematological features. NAC administration did not have a significant effect on the mean levels of Hb, Ht, number of erythrocytes, leukocytes and platelets (p> 0.05). However, NAC administration can reduce the degree of anemia and improve the condition of thrombocytopenia, leukopenia and lymphopenia. Conclusion: NAC administration can reduce hematological abnormalities HIV/AIDS patients undergoing ARV treatment. Keywords: ARV, Hematological abnormalities, HIV/AIDS, NAC.

scholarly journals Supplementation with a Highly Concentrated Docosahexaenoic Acid (DHA) in Non-Proliferative Diabetic Retinopathy: A 2-Year Randomized Double-Blind Placebo-Controlled Study

Antioxidants ◽  
2022 ◽  
Vol 11 (1) ◽  
pp. 116
Author(s):  
Purificación Piñas García ◽  
Francisco Javier Hernández Martínez ◽  
Núria Aznárez López ◽  
Luis Castillón Torre ◽  
Mª Eugenia Tena Sempere
Keyword(s):  
Diabetic Retinopathy ◽  
Placebo Group ◽  
Docosahexaenoic Acid ◽  
Proliferative Diabetic Retinopathy ◽  
Serum Levels ◽  
Nutritional Supplement ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Patients With Diabetes

We assessed the effect of a 2-year supplementation with a highly concentrated docosahexaenoic acid (DHA) product with antioxidant activity on non-proliferative diabetic retinopathy (NPDR) in a randomized double-blind placebo-controlled study. A total of 170 patients with diabetes were randomly assigned to the DHA group (n = 83) or the placebo group (n = 87). NPDR was diagnosed using non-contact slit lamp biomicroscopy examination, and classified into mild, moderate, and severe stages. Patients in the DHA group received a high rich DHA triglyceride (1050 mg/day) nutritional supplement, and those in the placebo group received olive oil capsules. The percentages of mild NPDR increased from 61.7% at baseline to 75.7% at the end of the study in the DHA group, and from 61.9% to 73.1% in the placebo group. Moderate NPDR stages decreased from 35.1% at baseline to 18.7% at the end of the study in the DHA group, and from 36.8% to 26.0% in the placebo group. In the DHA group, there were five eyes with severe NPDR at baseline, which increased to one more at the end of the study. In the placebo group, of two eyes with severe NPDR at baseline, one eye remained at the end of the study. Changes in visual acuity were not found. There were improvements in the serum levels of HbA1c in both groups, but significant differences between the DHA and the placebo groups were not found. In this study, the use of a DHA triglyceride nutraceutical supplement for 2 years did not appear to influence the slowing of the progression of NPDR.

scholarly journals Full-thickness Macular Hole Formation in Proliferative Diabetic Retinopathy

2021 ◽  
Author(s):  
MEI-CHI TSUI ◽  
Yi-Ting Hsieh ◽  
Tso-Ting Lai ◽  
Chun-Ting Lai ◽  
Hsuan-Chieh Lin ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Retinal Detachment ◽  
Macular Hole ◽  
Proliferative Diabetic Retinopathy ◽  
Full Thickness ◽  
Subsequent Formation ◽  
Full Thickness Macular Hole ◽  
Different Types ◽  
Before And After ◽  
Type 3

Abstract BackgroundTo investigate the formation pathways of full-thickness macular hole (FTMH) in proliferative diabetic retinopathy (PDR) with fibrovascular proliferation (FVP).MethodsTwenty-one consecutive patients (21 eyes) having PDR and FVP with optical coherence tomography (OCT) available before and after FTMH formation were retrospectively reviewed. Fundus abnormalities and OCT features were studied.ResultsFour different types of FTMH formation pathways in PDR were observed. Type 1 was characterized by epiretinal membrane (ERM) and/or vitreomacular traction (VMT) inducing foveoschisis, intraretinal cysts or foveal detachment, followed by formation of a FTMH or macular hole retinal detachment (MHRD). In type 2, ERM and/or FVP induced lamellar macular hole (LMH) with foveoschisis, followed by the formation of FTMH or MHRD. Type 3 was characterized by the initial tractional retinal detachment (TRD) with foveal cysts and/or foveoschisis and the subsequent formation of MHRD. Type 4 was characterized by TRD associated with foveal thinning, ensued by the formation of MHRD. Severity and locations of FVP varied with different types. Eyes with MHRD had poorer best-corrected visual acuity, higher proportion of active FVP, and higher rate of TRD.ConclusionFour types of FTMH formation pathways in PDR were identified and were quite different from those in idiopathic conditions. Spontaneous closure of FTMHs in PDR might be observed. The activity, severity and locations of FVP varied in PDR eyes destined to develop FTMHs.

scholarly journals Effect of Oral Supplementation with L-Carnitine on Performance Time in a 5000 m Race and Responses of Free Fatty Acid and Carnitine Concentrations in Trained-Endurance Athletes

2021 ◽  
Vol 10 (2) ◽  
pp. 5-11
Author(s):  
Mohammad Fayiz AbuMoh'd ◽  
◽  
Michael Yong Hwa Chia ◽  
Walid Alsababha ◽  
◽  
...  
Keyword(s):  
Fatty Acid ◽  
Free Fatty Acid ◽  
Physiological Responses ◽  
Endurance Athletes ◽  
Carnitine Supplementation ◽  
Double Blind ◽  
Oral Supplementation ◽  
Performance Time ◽  
Supplementation Period ◽  
Before And After

This study was designed to determine the effect of oral supplementation with L-carnitine on the performance time in a 5000 m race. In addition, free fatty acid, blood carnitine, lactate, and glucose responses to the race following the supplementation period were measured. Twenty male trained-endurance athletes were randomly divided into two groups (L-carnitine, n = 10 (22.13 ± 2.66 yrs) or placebo, n = 10 (21.63 ± 2.23 yrs)). The study was performed with a randomized, double-blind, placebo-controlled parallel-group, in which participants ingested an L-carnitine supplement or a placebo 2 × 1.5 g/day for 3 weeks. Athletes completed a 5000 m race before and after the supplementation period. Blood samples were collected from each athlete before and after the race, preand post-supplementation to measure the physiological responses. Data showed that there were no differences in performance time before (p=0.624) and after (p=0.407) supplementation period between groups and within a group (p>0.05). No differences existed in physiological responses between groups after supplementation before beginning the race (p>0.05), except for the blood carnitine level, which was significantly higher in the L-carnitine than the placebo (P=0.001) group. After the finish of the race, however, data showed better physiological responses in response to L-carnitine supplementation compared to the placebo group (p<0.05). In conclusion, although L-carnitine supplementation increases blood carnitine concentration, it has no beneficial effect on performance time of 5000 m race probably due to the short duration of the race; it might also have no ergogenic effect.

Sign in / Sign up

Export Citation Format

Share Document